Understanding and Inhibiting the P450 CYP24 enzyme, a target for cancer chemotherapeutics.

该项目属于国家研究优先事项，即促进和保持健康、健康和富有成效的老龄化。抑制CYP24为乳腺癌和前列腺癌提供了一个特定的靶点，这两种癌症分别是导致女性和男性死亡的第二大原因。这项拟议的研究将导致生产出CYP24抑制剂，阿德莱德的汉森研究所将在体内对其进行评估，作为潜在的抗癌药物。最后，我们在美国的合作者在计算机辅助缓蚀剂设计领域对澳大利亚的技术转让有很大的好处。

This project falls within the National Research Priority of Promoting and Maintaining Good Health in the category of ageing well and productively. CYP24 inhibition provides a particular target for breast and prostate cancer which are the second leading cause of death in women and men, respectively. The proposed research will result in the production of CYP24 inhibitors that will be assessed in vivo at the Hanson Institute in Adelaide as potential anti-cancer drugs. Finally, there is a significant benefit in technology transfer to Australia from our collaborators in the USA in the field of computer aided inhibitor design.